Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study
Song Chen,Feng Shi,Zhiqiang Wu,Liguang Wang,Hongjie Cai,Ping Ma,Yuanmin Zhou,Qicong Mai,Fan Wang,Shuangyan Tang,Wenquan Zhuang,Jiaming Lai,Xiaoming Chen,Huanwei Chen,Wenbo Guo
DOI: https://doi.org/10.2147/JHC.S417550
2023-07-28
Journal of Hepatocellular Carcinoma
Abstract:Song Chen, 1 Feng Shi, 2 Zhiqiang Wu, 3 Liguang Wang, 4 Hongjie Cai, 3 Ping Ma, 5 Yuanmin Zhou, 5 Qicong Mai, 2 Fan Wang, 3 Shuangyan Tang, 3 Wenquan Zhuang, 3 Jiaming Lai, 6 Xiaoming Chen, 2 Huanwei Chen, 4 Wenbo Guo 3 1 Department of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; 2 Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangzhou, People's Republic of China; 3 Department of Interventional Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; 4 Department of Hepatopancreatic Surgery, the First People's Hospital of Foshan, Foshan, People's Republic of China; 5 Department of Oncology, the Twelfth People's Hospital of Guangzhou, Guangzhou, People's Republic of China; 6 Center of Hepato-Pancreato-Biliary Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China Correspondence: Huanwei Chen, Department of Hepatopancreatic Surgery, the First People's Hospital of Foshan, Foshan, People's Republic of China, Email Wenbo Guo, Department of Interventional Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China, Email Purpose: The current therapeutic strategies for high-risk, unresectable hepatocellular carcinoma (HCC) patients demonstrate suboptimal outcomes. This study aimed to assess the clinical efficacy of the combined approach of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and tislelizumab, either with or without transhepatic arterial embolization (TAE), in managing HCC patients with portal vein tumor thrombus (PVTT) and significant tumor load. Patients and Methods: In this multicenter retrospective study, we analyzed patients diagnosed with primary, unresectable HCC presenting with PVTT and substantial tumor load who had undergone treatment with HAIC, lenvatinib, and tislelizumab, with or without TAE (referred to as the THLP or HLP group), between January 2019 and February 2022 across four medical centers in China. The outcomes included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS). Results: The study cohort comprised 100 patients, 50 each in the THLP and HLP groups. The THLP group demonstrated a significantly superior ORR (72% vs 52%, P =0.039). However, both groups exhibited comparable DCR (88% vs 76%, P =0.118), as assessed by the modified response evaluation criteria in solid tumors. The median OS and PFS for the entire cohort were 12.5 months (95% CI, 10.9– 14.8) and 5.0 months (95% CI, 4.2– 5.4), respectively. The THLP group exhibited a significantly extended OS (median, 14.1 vs 11.3 months, P =0.041) and PFS (median, 5.6 vs 4.4 months, P =0.037) in comparison to the HLP group. The most frequently reported treatment-related adverse events included abdominal pain and nausea, both reported by 59% of patients. Conclusion: The combination of HAIC, lenvatinib, tislelizumab, and TAE was feasible in HCC patients with PVTT and high tumor burden, with tolerable safety. Keywords: hepatocellular carcinoma, transhepatic arterial embolization, hepatic arterial infusion chemotherapy, lenvatinib, tislelizumab Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of cancer-related mortality globally. 1 First-line treatments such as ablation, surgical resection, and liver transplantation are traditionally reserved for early-stage HCC. 2 However, in China, an estimated 30%-62% of patients unfortunately present with portal vein tumor thrombus (PVTT), a complication associated with a bleak prognosis, limiting their treatment options. 3,4 Furthermore, a high tumor burden typically predicts poor systemic therapy outcomes in HCC patients with PVTT, which results in their exclusion from some prospective clinical trials. 5–7 The landscape of systemic treatment for HCC has been dramatically reshaped since the approval of the tyrosine kinase inhibitor (TKI) sorafenib in 2007, heralding a new era of therapeutic prospects. 8 This shift was then followed by the approval of further first-line single-agent systemic regimes, such as lenvatinib. 9 The exploration of immune checkpoint inhibitors (ICIs), particularly targeting programmed cell death 1 (PD-1), -Abstract Truncated-
oncology